NCT04959305 - A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension | Biotech Hunter

Enrollment

245

Participants

Timeline

Start Date

April 22, 2021

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions

Hypertension

Interventions

DRUG

HCP1803-3

Take it once daily for 8 weeks orally.

DRUG

RLD2003

Take it once daily for 8 weeks orally.

DRUG

RLD2004

Take it once daily for 8 weeks orally.

DRUG

RLD2005

Take it once daily for 8 weeks orally.

DRUG

HPP2003-3

Placebo drug. Take it once daily for 8 weeks orally.

DRUG

HPP2005

Placebo drug. Take it once daily for 8 weeks orally.

Trial Locations (1)

Donggguk University Ilsan Hospital, Goyang-si